Trial Search Results
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
This phase II/III trial studies how well gallium (Ga) 68-labeled gastrin-releasing peptide receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/magnetic resonance imaging (MRI) works in detecting prostate cancer in patients with negative computed tomography (CT) scan and elevated prostate-specific antigen levels after treatment with surgery or radiation. PET/MRI scans take both PET and MRI images at the same time and combine them into a single picture and is used to describe information regarding the function, as well as location and size of a tumor. 68Ga-RM2, a compound made of a radioactive agent linked to a pharmacological substance that is strongly attracted by a substance made by tumor cells, to detect prostate cancer. 68Ga-RM2 PET/MRI may be able to see smaller tumors than the standard of care contrast-enhanced CT or MRI scan
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Andrei Iagaru
Stanford Investigator(s):
Intervention(s):
- Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
- Procedure: Magnetic Resonance Imaging
- Procedure: Positron Emission Tomography
Phase:
Phase 2/Phase 3
Eligibility
Inclusion Criteria:
- Biopsy proven prostate adenocarcinoma
- Rising PSA after definitive therapy with prostatectomy or radiation therapy (external
beam or brachytherapy
- Post radical prostatectomy (RP) - American Urological Association (AUA)
recommendation
- PSA greater than 0.2 ng/mL measured 6-13 weeks after RP
- Confirmatory persistent PSA greater than 0.2 ng/mL
- Post-radiation therapy - American Society for Therapeutic Radiology and Oncology
(ASTRO)-Phoenix consensus definition
- Nadir plus (+) greater than or equal to 2 ng/mL rise in PSA
- No evidence of metastatic disease on conventional imaging, including a negative bone
scan for skeletal metastasis and negative contrast-enhanced CT
- Able to provide written consent
- Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group
[ECOG]/World Health Organization [WHO] equivalent)
Exclusion Criteria:
- Unable to provide informed consent
- Inability to lie still for the entire imaging time
- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the investigator, may significantly interfere
with study compliance
- Metallic implants
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pranav Hegde
650-721-4080
Not Recruiting